Holen Sie sich die Stockscreener-App
0.3598
4.59%
0.0158
Schlusskurs vom Vortag:
$0.344
Offen:
$0.32
24-Stunden-Volumen:
590.80K
Relative Volume:
0.95
Marktkapitalisierung:
$17.49M
Einnahmen:
$1.14M
Nettoeinkommen (Verlust:
$-56.27M
KGV:
-0.2964
EPS:
-1.2139
Netto-Cashflow:
$-51.94M
1W Leistung:
+1.93%
1M Leistung:
-5.79%
6M Leistung:
-42.92%
1J Leistung:
-66.06%
1-Tages-Spanne:
$0.32
$0.3613
1-Wochen-Bereich:
$0.295
$0.37
52-Wochen-Spanne:
$0.27
$2.38
Werewolf Therapeutics Inc Stock (HOWL) Company Profile
Firmenname
Werewolf Therapeutics Inc
Sektor
Branche
Telefon
617-952-0555
Adresse
200 TALCOTT AVENUE, WATERTOWN
Compare HOWL vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HOWL
Werewolf Therapeutics Inc
|
0.3598 | 17.49M | 1.14M | -56.27M | -51.94M | -1.2139 |
VRTX
Vertex Pharmaceuticals Inc
|
498.43 | 126.50B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
662.88 | 69.50B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
915.30 | 56.92B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
323.50 | 43.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.77 | 40.34B | 742.00K | -1.37B | -1.07B | -7.0731 |
Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-19 | Herabstufung | Wedbush | Outperform → Neutral |
| 2024-04-03 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-08-24 | Eingeleitet | Wedbush | Outperform |
| 2023-06-06 | Fortgesetzt | Jefferies | Buy |
| 2021-09-10 | Eingeleitet | BofA Securities | Buy |
| 2021-05-25 | Eingeleitet | Evercore ISI | Outperform |
| 2021-05-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-25 | Eingeleitet | Jefferies | Buy |
| 2021-05-25 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Werewolf Therapeutics Inc Aktie (HOWL) Neueste Nachrichten
Werewolf Therapeutics director Luke Evnin sells $44,749 in stock - Investing.com
Form 4 Werewolf Therapeutics Inc For: 8 July By Investing.com - Investing.com Canada
Werewolf Therapeutics director Luke Evnin sells $44,749 in stock By Investing.com - Investing.com Canada
Werewolf Therapeutics (HOWL) director-linked funds sell 143,199 shares - Stock Titan
Werewolf Therapeutics outlines its immuno-oncology strategy as Nasdaq-listed biotech - Ad-hoc-news.de
[144] Werewolf Therapeutics, Inc. SEC Filing - Stock Titan
RA Capital trims Werewolf Therapeutics (HOWL) stake below 5% threshold - Stock Titan
Form 13D/A WEREWOLF THERAPEUTICS For: 2 July By Investing.com - Investing.com South Africa
Werewolf Therapeutics (HOWL) price target increased by 20.19% to 6.38 - MSN
Werewolf Therapeutics, Inc. Financial Disclosures & SEC Filings - TradingView
Werewolf Therapeutics director Luke Evnin sells $47,125 in stock By Investing.com - Investing.com South Africa
Form 4 Werewolf Therapeutics Inc For: 29 June By Investing.com - Investing.com South Africa
Form 144 Werewolf Therapeutics For: 29 June By Investing.com - Investing.com South Africa
Werewolf Therapeutics director Luke Evnin sells $47,125 in stock - Investing.com
Entities tied to Werewolf Therapeutics (HOWL) director Luke Evnin sell 157K shares - Stock Titan
Werewolf Therapeutics, Inc. Actuals & Estimates (NASDAQ:HOWL) - TradingView
Form 13D/A WEREWOLF THERAPEUTICS For: 26 June By Investing.com - Investing.com South Africa
Werewolf Therapeutics Inc (HOWL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
RA Capital reports 6% Werewolf Therapeutics (HOWL) stake after June share sales - Stock Titan
Werewolf Therapeutics details cancer pipeline progress, shares watched by biotech investors - Ad-hoc-news.de
Werewolf Therapeutics Inc (HOWL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Werewolf Therapeutics Inc (HOWL) Institutional Confidence - TradingKey
Ra Capital sells $145,918 of Werewolf Therapeutics (HOWL) stock By Investing.com - Investing.com Australia
Ra Capital sells $145,918 of Werewolf Therapeutics (HOWL) stock - Investing.com UK
[SCHEDULE 13D/A] Werewolf Therapeutics, Inc. Amended Major Shareholder Report - Stock Titan
Form 13D/A WEREWOLF THERAPEUTICS For: 22 June By Investing.com - Investing.com South Africa
Form 4 Werewolf Therapeutics Inc For: 22 June By Investing.com - Investing.com Nigeria
RA Capital funds trim Werewolf Therapeutics (HOWL) stake with 416,911-share sale - Stock Titan
RA Capital Management Reduces Stake in Werewolf Therapeutics Inc - GuruFocus
Werewolf Therapeutics Inc (HOWL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Werewolf Therapeutics Inc (HOWL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Werewolf Therapeutics Inc (HOWL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Werewolf Therapeutics Inc (HOWL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Werewolf Therapeutics Inc (HOWL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Werewolf Therapeutics Inc (HOWL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Ra Capital Management reduces Werewolf Therapeutics stake by $173,757 - Investing.com India
RA Capital trims Werewolf Therapeutics (HOWL) stake with 448,836-share sale - Stock Titan
RA Capital adjusts Werewolf Therapeutics (HOWL) stake to 10.6% ownership - Stock Titan
Finanzdaten der Werewolf Therapeutics Inc-Aktie (HOWL)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.27%
0.61%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):